Cetuximab Extends Survival In Advanced Non-Small Cell Lung Cancer

AudioMedica News
AudioMedica News
Cetuximab Extends Survival In Advanced Non-Small Cell Lung Cancer
Loading
/
Robert Pirker
Robert Pirker

ROBERT PIRKER , Medical University of Vienna
Phase III study results have detected improvements in overall survival among patients with advanced non-small cell lung cancer treated with a monoclonal antibody targeted to the epidermal growth factor receptor: EGFR. Robert Pirker told the Turin congress he thinks is an emerging role for EGRF-targeted antibodies in lung cancer for patients who test positive for the epidermal growth factor receptor. He discussed the data with Peter Goodwin.



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/080316_robert_pirker.mp3]

Further reading